PE20070546A1 - TALNETANT PHARMACEUTICAL COMPOSITIONS - Google Patents

TALNETANT PHARMACEUTICAL COMPOSITIONS

Info

Publication number
PE20070546A1
PE20070546A1 PE2006001182A PE2006001182A PE20070546A1 PE 20070546 A1 PE20070546 A1 PE 20070546A1 PE 2006001182 A PE2006001182 A PE 2006001182A PE 2006001182 A PE2006001182 A PE 2006001182A PE 20070546 A1 PE20070546 A1 PE 20070546A1
Authority
PE
Peru
Prior art keywords
povidone
mannitol
talnetant
ratio
surfactant
Prior art date
Application number
PE2006001182A
Other languages
Spanish (es)
Inventor
Jeffrey Brum
Patrick FAULKNER
Rennan Pan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37441932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070546(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20070546A1 publication Critical patent/PE20070546A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (i) UN ANTAGONISTA DEL RECEPTOR NK3 TAL COMO TALNETANT ((S)-(-)-N-(ALFA-ETILBENCIL)-3-HIDROXI-2-FENILQUINOLINA-4-CARBOXAMIDA), (ii) POVIDONA, (iii) MANITOL Y (iv) UN TENSIOACTIVO, DONDE LA PROPORCION DE POVIDONA A MANITOL ES 0,45:1 O MAYOR Y LA PROPORCION DE POVIDONA Y MANITOL (JUNTOS) A TALNETANT ES 0,3:1 O MAYOR. LA PROPORCION DE POVIDONA A MANITOL, DE PREFERENCIA ES ENTRE 0,45:1 Y 1:1 Y LA PROPORCION DE (MANITOL + POVIDONA) A TALNETANT, DE PREFERENCIA ES ENTRE 0,3:1 Y 5:1. EL TENSIOACTIVO EMPLEADO PUEDE SER UN TENSIOACTIVO IONICO TAL COMO LAURIL-SULFATO SODICO O DIOCTIL-SULFOSUCCINATO SODICO (DOCUSATO SODICO) O UN TENSIOACTIVO NO IONICO TAL COMO POE-POLIOXIPROPILENGLICOL. DICHA COMPOSICION ES PARA ADMINISTRACION ORAL Y ES UTIL EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL TALES COMO DEPRESION, ANSIEDAD RELACIONADA CON DEPRESION, DISTIMIA, ENTRE OTRASREFERRED TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: (i) AN ANTAGONIST OF THE NK3 RECEPTOR SUCH AS TALNETANT ((S) - (-) - N- (ALPHA-ETHYLBENZYL) -3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE), ( ii) POVIDONE, (iii) MANNITOL AND (iv) A SURFACTANT, WHERE THE RATIO OF POVIDONE TO MANNITOL IS 0.45: 1 OR GREATER AND THE RATIO OF POVIDONE AND MANNITOL (TOGETHER) TO TALNETANT IS 0.3: 1 OR GREATER . THE RATIO OF POVIDONE TO MANNITOL, OF PREFERENCE IS BETWEEN 0.45: 1 AND 1: 1 AND THE RATIO OF (MANNITOL + POVIDONE) TO TALNETANT, OF PREFERENCE IS BETWEEN 0.3: 1 AND 5: 1. THE SURFACTANT USED MAY BE AN IONIC SURFACTANT SUCH AS LAURYL-SODIUM SULFATE OR SODIUM DIOCTIL-SULFOSUCCINATE (SODIUM DOCUSATE) OR A NON-IONIC SURFACTANT SUCH AS POE-POLYOXYPROPYLENGLYCOL. SUCH COMPOSITION IS FOR ORAL ADMINISTRATION AND IS USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS DEPRESSION, ANXIETY RELATED TO DEPRESSION, DISTIMIA, AMONG OTHERS

PE2006001182A 2005-09-30 2006-09-28 TALNETANT PHARMACEUTICAL COMPOSITIONS PE20070546A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72215305P 2005-09-30 2005-09-30

Publications (1)

Publication Number Publication Date
PE20070546A1 true PE20070546A1 (en) 2007-07-04

Family

ID=37441932

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001182A PE20070546A1 (en) 2005-09-30 2006-09-28 TALNETANT PHARMACEUTICAL COMPOSITIONS

Country Status (7)

Country Link
US (1) US20080255193A1 (en)
EP (1) EP1940358A2 (en)
JP (1) JP2009510121A (en)
AR (1) AR058676A1 (en)
PE (1) PE20070546A1 (en)
TW (1) TW200803854A (en)
WO (1) WO2007041479A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL220269B1 (en) * 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Composite carrier of powdered medicines, method of production the medicine carrier and equipment for production of particles of composite carrier
SG10201706265PA (en) * 2010-03-19 2017-08-30 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
EP3093011B1 (en) * 2010-12-17 2021-03-24 Merck Patent GmbH Method for the preparation of directly tablettable mannitol
CN109897813A (en) * 2019-03-21 2019-06-18 贵州医科大学 The construction method of helicobacter pylori cagA gene Inactivating mutations strain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY134211A (en) * 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
RU2006138054A (en) * 2004-03-30 2008-05-10 Смиткайн Бичам Корпорейшн (Us) SPRAY DRIED PHARMACEUTICAL COMPOSITIONS

Also Published As

Publication number Publication date
EP1940358A2 (en) 2008-07-09
WO2007041479A2 (en) 2007-04-12
WO2007041479A3 (en) 2007-10-11
JP2009510121A (en) 2009-03-12
AR058676A1 (en) 2008-02-20
US20080255193A1 (en) 2008-10-16
TW200803854A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
BRPI0514474A (en) multiparticulate
RS52199B (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
Umbricht et al. Risperidone: efficacy and safety
CL2008001268A1 (en) Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain.
ECSP088239A (en) COMPOSITION OF SUSTAINED DRUG RELEASE
PE20060505A1 (en) PHARMACEUTICAL COMPOSITION OF 4 {4- [3- (4-CHLORO-3-TRIFLUOROMETHYLPHENYL) -UREIDO] -3-FLUORO-PHENOXY} -PYRIDINE-2-CARBOXYL ACID IN THE FORM OF A SOLID DISPERSION USEFUL IN HYPERPERATIVE DISORDERS
CL2018001420A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853)
AR069349A1 (en) USE OF TRPV1 RECEIVER ANTAGONISTS FOR THE TREATMENT OF THE EYE AND EYE PAIN
ECSP077421A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1
CO2019000945A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
ECSP10010684A (en) MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY.
CR8891A (en) ANTAGONISM OF THE ACTIVITY OF THE INTERLEUQUINE RECEIVER 21
CO2019000938A2 (en) Nmda spiro-lactam modulators and methods of use thereof
CO2019000943A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
PE20070216A1 (en) NEW PHARMACEUTICAL COMPOSITIONS INCLUDING LEVETIRACETAM AND PROCESS FOR ITS PREPARATION
CO2019000944A2 (en) Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof
CL2008000647A1 (en) Indazole derived compounds; pharmaceutical composition; yuse in the treatment of diseases such as pain, chronic inflammatory disorders, CNS disorders, among others.
CO2019000941A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
MXPA06014470A (en) Ophthalmic formulations including selective alpha 1 antagonists.
CL2011000144A1 (en) Compounds derived from benzo (1,4) dioxin-2-ylmethyl-sulfamide; pharmaceutical compositions containing them; process to prepare them and use in the treatment of anxiety, epilepsy, pain, substance abuse, related disorders, among others.
PE20181523A1 (en) TREATMENT OF LUPUS NEFRITIS USING LAQUINIMOD
NO20064054L (en) Therapeutic combinations of atypical antipsychotics with corticotropin release factor antagonists
AR060836A1 (en) A TRANS-MUCOSA DISK TO ADMINISTER AN ACTIVE AGENT, A TRANS-MUCOSA COMPOSITION AND THE METHOD OF ADMINISTRATION OBTAINED
PE20081106A1 (en) CAPECITABIN PEDIATRIC TABLETS
CL2007000396A1 (en) Compounds derived from benzoyl-piperidine, 5ht2 / d3 receptor modulators; pharmaceutical composition that includes them; and their use in the treatment and / or prevention of delsnc pathologies, such as psychosis, schizophrenia, depression, anxiety, drug addiction and cognitive problems.

Legal Events

Date Code Title Description
FC Refusal